FibroBiologics Files S-1/A Amendment for IPO
Ticker: FBLG · Form: S-1/A · Filed: Jun 4, 2024 · CIK: 1958777
Sentiment: neutral
Topics: ipo, sec-filing, amendment
TL;DR
FibroBiologics filed an S-1/A amendment for its IPO. Details updated.
AI Summary
FibroBiologics, Inc. filed an S-1/A amendment on June 4, 2024, for its initial public offering. The company, incorporated in Delaware, is in the pharmaceutical preparations sector and is headquartered in Houston, Texas. This filing is an amendment to a previous registration statement (No. 333-278938) and provides updated information for potential investors.
Why It Matters
This S-1/A filing provides updated information for investors considering an initial public offering, detailing the company's financial and operational status.
Risk Assessment
Risk Level: medium — As an S-1/A filing for an IPO, it indicates the company is seeking public investment, which inherently carries risks associated with early-stage or growth companies.
Key Numbers
- 2834 — SIC Code (Pharmaceutical Preparations industry)
- 86-3329066 — IRS Number (Employer Identification Number)
Key Players & Entities
- FibroBiologics, Inc. (company) — Registrant
- June 4, 2024 (date) — Filing date
- 333-278938 (registration_number) — SEC registration number
- Pete O'Heeron (person) — Chief Executive Officer
- Brian Fenske (person) — Legal counsel contact
- Norton Rose Fulbright US LLP (company) — Legal counsel
FAQ
What is the purpose of this S-1/A filing?
This S-1/A filing is an amendment to the Registration Statement under the Securities Act of 1933, providing updated information for FibroBiologics, Inc.'s initial public offering.
When was this amendment filed with the SEC?
This amendment was filed with the Securities and Exchange Commission on June 4, 2024.
What is the principal executive office address of FibroBiologics, Inc.?
The principal executive offices are located at 455 E. Medical Center Blvd. Suite 300, Houston, Texas 77598.
Who is the Chief Executive Officer of FibroBiologics, Inc.?
Pete O'Heeron is the Chief Executive Officer of FibroBiologics, Inc.
What is the company's Standard Industrial Classification (SIC) code?
The company's SIC code is 2834, which corresponds to Pharmaceutical Preparations.
Filing Stats: 4,507 words · 18 min read · ~15 pages · Grade level 14.5 · Accepted 2024-06-04 14:36:46
Key Financial Figures
- $0.00001 — ne share of our common stock, par value $0.00001 per share (the “common stock&rdqu
- $11.48 — have assumed a public offering price of $11.48 per Unit, which was the last reported s
Filing Documents
- forms-1a.htm (S-1/A) — 1550KB
- ex1-1.htm (EX-1.1) — 154KB
- ex4-4.htm (EX-4.4) — 111KB
- ex10-24.htm (EX-10.24) — 272KB
- ex23-2.htm (EX-23.2) — 5KB
- ex107.htm (EX-FILING FEES) — 18KB
- forms-1_001.jpg (GRAPHIC) — 4KB
- chart_1.jpg (GRAPHIC) — 109KB
- forms-1_003.jpg (GRAPHIC) — 30KB
- forms-1_004.jpg (GRAPHIC) — 28KB
- 0001493152-24-022517.txt ( ) — 2348KB
RISK FACTORS
RISK FACTORS 10 CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS 64 MARKET AND INDUSTRY DATA 65 TRADEMARKS, SERVICE MARKS AND TRADENAMES 66
USE OF PROCEEDS
USE OF PROCEEDS 67 DIVIDEND POLICY 67
DILUTION
DILUTION 67 CAPITALIZATION 68 MANAGEMENT 6 9 EXECUTIVE AND DIRECTOR COMPENSATION 76 CERTAIN RELATIONSHIPS AND RELATED PERSON TRANSACTIONS 81 PRINCIPAL STOCKHOLDERS 82 DESCRIPTION OF OUR SECURITIES 83 PLAN OF DISTRIBUTION 88 CERTAIN MATERIAL U.S. FEDERAL INCOME TAX CONSEQUENCES 94 LEGAL MATTERS 101 EXPERTS 101 WHERE YOU CAN FIND ADDITIONAL INFORMATION 101 INCORPORATION OF CERTAIN DOCUMENTS BY REFERENCE 102 You should rely only on the information contained in this prospectus or contained in any free writing prospectus filed with the Securities and Exchange Commission. Neither we nor the placement agent have authorized anyone to provide any information different from, or in addition to, the information contained in this prospectus and in any free writing prospectuses we have prepared or that have been prepared on our behalf or to which we have referred you. Neither we nor the placement agent take responsibility for, and can provide no assurance as to the reliability of, any other information that others may give you. We are offering to sell, and seeking offers to buy, the securities only under the circumstances and in jurisdictions where it is lawful to do so. The information contained in this prospectus is current only as of its date, regardless of the time of delivery of this prospectus or of any sale of our securities. Our business, financial condition, results of operations and prospects may have changed since such date. For investors outside the United States: Neither we nor the placement agent have done anything that would permit the use of or possession or distribution of this prospectus or any related free writing prospectus in any jurisdiction where action for that purpose is required, other than in the United States. Persons outside the United States who come into possession of this prospectus must inform themselves about, and observe any restrictions relating to, the offering of the securities and the distribution of